CYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS INDEX Page Unaudited Interim Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Loss fo

THERAPEUTICS LIMITED AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THERAPEUTICS LIMITED AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE LOSS FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2025

accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

THERAPEUTICS LIMITED AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITIONS

OF DECEMBER 31, 2024 AND JUNE 30, 2025

accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

THERAPEUTICS LIMITED AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

THE SIX MONTHS ENDED JUNE 30, 2024 AND 2025

accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

THERAPEUTICS LIMITED AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

SIX MONTHS ENDED JUNE 30, 2024 AND 2025

accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements

THERAPEUTICS LIMITED AND SUBSIDIARIES

to the Unaudited Interim Condensed Consolidated Financial Statements

1 General Information

unaudited interim condensed consolidated financial statements are the unaudited interim financial statements of CytoMed Therapeutics

Limited (the "Company") and its subsidiaries (the "Group"), for the six months ended June 30, 2025 (the "Financial

Company was incorporated in the Republic of Singapore on March 9, 2018. The Company is a public limited company incorporated and domiciled

in Singapore with registered office situated at 1 Commonwealth Lane, #08-22, Singapore 149544. The Company is headquartered in Singapore

and conducts its operations domestically and in Malaysia. The Company is listed on the Nasdaq Stock Exchange under the ticker symbol

"GDTC" on April 14, 2023.

principal activities of the Group are to carry on the business of innate immune cell-based immunotherapy, pluripotent stem cell-based

therapy and undertaking the research and development of immune cell and stem cell-based therapy. The Group conducts its primary operations

through its directly held wholly owned subsidiary that is incorporated and domiciled in Malaysia, namely CytoMed Therapeutics (Malaysia)

Sdn. Bhd., which is principally engaged in manufacturing innate immune cell-based immunotherapy and pluripotent stem cell-based therapy

and consultancy services and undertaking the research and development of immune cell and stem cell-based therapy for advancing cellular

immunotherapy to treat cancer.

August 15, 2024, IPSC Depository Sdn. Bhd., an indirect subsidiary of the Company, completed the acquisition of the license and certain

assets of Cellsafe International Sdn Bhd (In Liquidation), a Malaysian cord blood banking service provider.

principal activities of the subsidiaries of the Company (the "Company" or collectively known as the "Group")

2 Summary of significant accounting policies

unaudited condensed interim consolidated financial statements for the six-month ended June 30, 2025 have been prepared in accordance

with IAS 34 Interim Financial Reporting.

unaudited interim consolidated financial statements do not include all the information and footnotes required by the International Financial

Reporting Standards ("IFRS") for complete financial statements. Certain information and note disclosures normally included

in the annual financial statements prepared in accordance with the IFRS have been condensed or omitted consistent with Article 10 of

Regulation S-X. In the opinion of the Company's management, the unaudited interim consolidated financial statements have been prepared

on the same basis as the audited financial statements and include all adjustments, in normal recurring nature, as necessary for the fair

statements of the Company's financial positions as of June 30, 2025, and results of operations and cash flows for the six-month

period ended June 30, 2025. The unaudited interim condensed consolidated statements of financial positions as of December 31, 2024 has

been derived from the audited financial statements at that date but does not include all the information and footnotes required by the

IFRS. Interim results of operations are not necessarily indicative of the results expected for the full fiscal year or for any future

period. These financial statements should be read in conjunction with the audited consolidated financial statements as of and for the

years ended December 31, 2024, 2023 and 2022, and related notes included in the Company's audited consolidated financial statements.

accounting policies adopted are consistent with those of the previous financial year except that in the current financial year, the Group

has adopted all the new and amended standards which are relevant to the Group and are effective for annual financial period beginning

on January 1, 2025. The adoption of these standards did not have any material effect on the unaudited interim condensed consolidated

financial statements of the Group.

are a number of standards, amendments to standards, and interpretations, which have been issued by the International Accounting Standards

Board, that are effective in future accounting periods and the Group has not decided to early adopt. Unless otherwise disclosed, the

Group is currently evaluating the potential impact of adopting these standards on its consolidated financial statements and related disclosures

in the year of initial application.

translations from Singapore dollars to U.S. dollars and from U.S. dollars to Singapore dollars in this Report are made at a rate of S$1.2719

to U.S.$1.00, the exchange rate in effect as of June 30, 2025 as set forth in the H.10 statistical release of the U.S. Board of Governors

of the Federal Reserve System.

liquidity risk management implies sufficient cash to finance the Group's and the Company's operations and development activities.

The Group manages the liquidity risk by maintaining a level of cash and cash equivalents deemed adequate to finance the Group's

business operations and development activities. The Group's objective is to maintain a balance between continuing of funding and

flexibility through the use of borrowings.

of June 30, 2025, the Group has negative cash flow from operating activities of S$1,599,164. The Group's working capital

was S$3,380,056. As of June 30, 2025, the Group had S$2,854,958 in cash and bank balances, which is unrestricted as to withdrawal and

use as of June 30, 2025. In view of these circumstances, the management of the Group has given consideration to the future liquidity

and performance of the Group and its available sources of finance in assessing whether the Group will have sufficient financial resources

to continue as a going concern, at least, for the next twelve months from the date of this report.

3 Significant accounting judgements and estimates

preparation of the unaudited condensed interim consolidated financial statements requires management to make judgements, estimates and

assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities

at the end of each reporting period. However, uncertainty about these assumptions and estimates could result in outcomes that require

a material adjustment to the carrying amount of the asset or liability affected in the future periods.

significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty

were the same as those that applied to the consolidated financial statements as of and for the year ended December 31, 2024.

4 Segment information

Group has identified two operating segments i.e. (i). the business of innate immune cell-based immunotherapy, pluripotent stem cell-based

therapy and undertaking the research and development of immune cell and stem cell-based therapy as well as (ii) the business of processing

and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy.

Group's revenues are primarily derived from the provision of cord blood unit banking and retrieval services ("private blood

banking services"). The Group derives revenue from transfer of services over time or at a point in time in the following major

contract liability is recognized if a payment is received or a payment is due (whichever is earlier) from a customer before the Group

transfers the related goods or services mainly derived from the private blood banking business. Contract liabilities are recognized as

revenue when the Group performs under the contract (i.e., transfers control of the related goods or services to the customer.

liabilities are reported as contract liabilities on a contract by contract basis at the end of each reporting period. Significant changes

in the contract liabilities balances during the financial year was mainly arriving from the increases due to cash received, excluding

amounts recognized as revenue during the financial year.

expects that the approximate transaction price allocated to unsatisfied performance obligations as at the end of the reporting periods

may be recognized as revenue in the next reporting periods as follows: